WO1996039927A1 - Method for noninvasive intermittent and/or continuous hemoglobin, arterial oxygen content, and hematocrit determination - Google Patents

Method for noninvasive intermittent and/or continuous hemoglobin, arterial oxygen content, and hematocrit determination Download PDF

Info

Publication number
WO1996039927A1
WO1996039927A1 PCT/US1996/009148 US9609148W WO9639927A1 WO 1996039927 A1 WO1996039927 A1 WO 1996039927A1 US 9609148 W US9609148 W US 9609148W WO 9639927 A1 WO9639927 A1 WO 9639927A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
tissue compression
hemoglobin
measuring
volume
Prior art date
Application number
PCT/US1996/009148
Other languages
French (fr)
Inventor
Dietrich Gravenstein
J. E. W. Beneken
Samsun Lampotang
Nikolaus Gravenstein
Michael A. Brooks
Gordon L. Gibby
Robert J. Atwater
Original Assignee
Blackbox, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blackbox, Inc. filed Critical Blackbox, Inc.
Priority to AU62561/96A priority Critical patent/AU6256196A/en
Publication of WO1996039927A1 publication Critical patent/WO1996039927A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/14551Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14535Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring haematocrit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/41Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/417Evaluating particular organs or parts of the immune or lymphatic systems the bone marrow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813Specially adapted to be attached to a specific body part
    • A61B5/6814Head
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813Specially adapted to be attached to a specific body part
    • A61B5/6814Head
    • A61B5/6815Ear
    • A61B5/6816Ear lobe
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813Specially adapted to be attached to a specific body part
    • A61B5/6814Head
    • A61B5/682Mouth, e.g., oral cavity; tongue; Lips; Teeth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813Specially adapted to be attached to a specific body part
    • A61B5/6825Hand
    • A61B5/6826Finger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/683Means for maintaining contact with the body
    • A61B5/6838Clamps or clips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813Specially adapted to be attached to a specific body part
    • A61B5/6824Arm or wrist

Definitions

  • Partial pressure of oxygen (P0 2 ) in blood, percent hematocrit (Hct), percent arterial hemoglobin saturation (SaO j ), gram-percent total hemoglobin (THb), and arterial oxygen content (Ca0 2 ) are all readily available to the physician in modern hospitals. Unfortunately, however, measurement of these variables has until recently always required an invasive arterial puncture or phlebotomy. Once the whole blood sample is obtained, analysis is accomplished using spectrophotometric and chemical means.
  • Pulse oximeter design is well documented. It utilizes two light-emitting diodes (LED). Each LED is a light-emitting diode (LED).
  • LED emits a specific wavelength of light that is transmitted through the tissues to a photodetector.
  • An electrical signal consisting of two components is generated by the photodetector receiving the LED emission. There is an invariant direct current (DC) component to the signal which represents ambient background light and transmission of light through invariant, that is, nonpulsatile tissues such as skin, bone, and, to a certain extent, veins.
  • DC direct current
  • AC alternating current
  • THb, Ca0 2 continues to require arterial puncture or phlebotomy. Skin puncture procedures are painful to the patient, time consuming, and provide opportunities for infection. There is a great need for a rapid and accurate noninvasive means of assessing THb, Ca0 2 , and Hct. Such an assessment means would enable the health care provider to quickly evaluate and follow a patient's circulating blood status. Questions of hemodilution during volume expansion in the field, ER, ICU, and OR would be rapidly answered. Hemoconcentration after blood transfusion, hemodialysis or bone marrow transplantation could be followed without repeated venipuncture. Furthermore, many "routine" screening phlebotomies to assess THb and Hct such as for preoperative laboratory studies in children and adults could be eliminated.
  • the subject invention concerns a novel means and device for noninvasive determination of total hemoglobin, arterial oxygen content, and hematocrit.
  • these determinations can be made intermittendy and/or continuously.
  • the novel procedure described here is painless and eliminates the need for skin punctures. It is cost effective because there is no need for needles, syringes, gloves, bandages, or skilled technicians.
  • critical data can be obtained in seconds rather than minutes or hours and continuously rather than episodically.
  • the determination of the blood parameters of interest is accomplished by measuring the change in the mass of hemoglobin (Hb0 2 , RHb, or THb) resulting from a measured or controlled change in volume of blood
  • Hb0 2 , RHb, or THb the change in the mass of hemoglobin
  • THb the change in the mass of hemoglobin
  • the change of mass of hemoglobin species associated with a controlled change in volume can be measured photometrically by passing light of appropriate wavelength(s) through a portion of the body.
  • the attenuation of the light which can be detected by a photometer is related to the amount of hemoglobin species in the blood being analyzed.
  • changes occur in the volume or hemoglobin species concentration of blood being analyzed corresponding changes in the mass of hemoglobin species can be measured.
  • Figure 1 is a schematic representation of one embodiment of the invention where Hb0 2 is measured directly and a pulse oximeter is utilized.
  • Figure 2 is a schematic representation of one embodiment of the invention where Hb0 2 is measured directly and a pulse oximeter is not explicitly incorporated.
  • FIG. 3 is a schematic representation of one embodiment of the invention where THb is measured directly and a pulse oximeter is not explicitly incorporated.
  • Figure 4 is a schematic representation of one embodiment of the invention where desired hemoglobin species is/are measured and a pulse oximeter is not explicitly incorporated.
  • Figure 5 is a diagram of the Caliper-mounted device for collection of dog data.
  • Figure 6 is dog data total hemoglobin (g/dL) versus ln(VJV])/Del-X (mm *1 ).
  • Figure 7 is a diagram of the device used for collecting human data.
  • Figure 8 is data of human population total hemoglobin (g/dL) versus lnCVJVJ/Del-X (mm '
  • Figure 9 is a data collection device.
  • Hb0 2 (g/dL) THb Sa0 2 .
  • oxygen content can be calculated if oxyhemoglobin is known. Therefore, if the mass of oxyhemoglobin molecules [mHb0 2 (g)] in a given volume [V(dL)] is known, the oxygen content of that volume can be determined. Stated another way, if a change in the mHb0 2 can be measured along with the corresponding change in volume, oxygen content can be measured. This relationship can be written
  • Hb0 2 (g/dL) [mHb0 2t2 _ mHbOai ]/[Vt2 - Vu], (4)
  • Hb0 2 ⁇ mHbO ⁇ V
  • ⁇ mHbO is the change in mass of the HbO, species and ⁇ V is the measured corresponding change in volume.
  • the value for ⁇ mHb0 2 if mHb0 2 is measured directly, can be calculated using a signal generated by a pulse oximeter, for example. mHb0 2 can also be determined indirectly. Indirect determination requires accurate Sp0 2 and either RHb or THb values. Sa0 2 and Sp0 2 are known to be close to each other. If RHb and Sp0 2 are known, then
  • Hb0 2 THb-RHb, (8)
  • Hb0 2 [(RHb x 100)/(100-Sp ⁇ 2 )]-RHb. (9)
  • Equation (2) can be utihzed for indirect mHb0 2 determination and equation (8) will then permit calculation of RHb.
  • Equations (4) and (5) The invention can be practiced utilizing Equations (4) and (5).
  • the same equations may be used for any hemoglobin species, e.g. for THb, using a wavelength of 810 nm. These equations are clinically useful approximations of the pertinent biological phenomena to be measured by the subject invention. Additional terms can be added to Equations (4) and (5). These additional terms reflect the relatively small effects which are attributable to respiration and other physiological activities.
  • THb(g/dL) Ca0 2 (mL 0 2 /dL)/[Sp0 2 x 1.39(mL 0 2 /g Hb0 2 )]. (10)
  • RBC red blood cell
  • the claimed device comprises a small appliance that is easily attached to the patient.
  • the device can be attached onto the finger, earlobe, wrist, lips, nares, tongue, cheek, or some other site.
  • the device further comprises a signal processing part that also displays the results.
  • the device displays Ca0 2 , THb, and an estimate of Hct continuously or intermittently.
  • MetHb, and Carboxy Hb (COHb), glucose, bilirubin, etc. can also be quantified.
  • the device does not necessarily require incorporation into a pulse oximeter, or similar device, to determine THb. Instead, an Sp0 2 value can be obtained via the digital output port of a pulse oximeter, or similar device, and input into the proposed device.
  • the device could be incorporated into a pulse oximeter (or similar device), as illustrated in Figure 1, or operate as a unit distinct from it as diagrammed in Figures 2, 3 and 4.
  • Example 17 provides in vivo results obtained using this embodiment of the invention.
  • the extension of this method to monitoring of other relevant blood constituents, besides hemoglobin, such as glucose, bilirubin or cholesterol is also described.
  • tissue compression method for deterniining THb and other blood constituents in vivo is similar to pulse oximetry theory.
  • the compression method differs from pulse oximetry in that actual concentrations of hemoglobin (or other light absorbing constituents such as glucose, bilirubin or cholesterol) may be determined.
  • the third compartment consists of immobile, sohd tissues.
  • the major light absorbers are species of hemoglobin: RHb, Hb0 2 , COHb and metHb.
  • COHb typically comprises 3% to 5% of all hemoglobin and as much as 10% to 15% in smokers.
  • MetHb is typically less than 1% of the total except in rare disease states.
  • the remaining hemoglobin is primarily split between RHb and Hb0 2 , depending on blood oxygen saturation. Not only are extinction coefficients different for each of these species, but the coefficients vary with wavelength of light.
  • K ⁇ ,, Km ⁇ and K ⁇ are extinction coefficients for RHb, Hb0 2 , and nonblood tissues and Cm,
  • 0 ⁇ 02 and C f are concentrations of RHb, Hb0 2 and the light absorbing substances in the nonblood tissues, respectively.
  • the subscript "1" indicates that measurements are made at a first point in time.
  • Optical path lengths are designated as L ⁇ , through blood and L-- through nonblood tissues.
  • Equation (13) may be duplicated for a second point in time, designated by the subscript "2", at which point the optical path length through the blood is different than at the first point in time:
  • equations (13) and (14) accomplishes three things. First, the light source intensity , is eliminated. Thus, lo need not be measured. Second, the last terms of equations (13) and (14) that account for nonblood tissues are also eliminated so that person-to-person differences need not be known. This second item is what makes it possible for our method and device to work on the general population without the need for individual calibration. Third, only the ratio of the variables I 2 and I, needs to be known and not their actual values. This means that measurement calibration for actual light intensity is not necessary. The equation that results from the subtraction is as follows:
  • a simplified model comprises hght passing from a source on one side of a volume of living tissue to a detector on the other side.
  • the blood and less mobile nonblood tissues occupy separate and distinct compartments.
  • the optical path length through blood decreases while the path length through nonblood tissues is unchanged.
  • the term ⁇ L ⁇ in equation (15) is due entirely to changes in the blood optical path length. If the actual value of ⁇ L B is known, then the only unknown values left in equation (15) are the concentrations of RHb and Hb0 2 (i.e., C ⁇ and Cm ⁇ , respectively).
  • K ⁇ is an empirically determined constant and ⁇ L ⁇ is measured or controlled by the device that compresses the tissue, THb may be calculated.
  • the tissue compression method described here may be used to determine actual blood constituent concentrations instead of just ratios of concentrations like the pulse oximeter does. Since the method involves compressing tissues to change the optical path length through blood, the optical path length change is controlled and not dependent on the variability of natural pulsations, as in pulse oximetry. Thus, large signals on the order to 10% to 40% of the DC value are possible on demand with consequent improvements in signal to noise ratio and accuracy of blood parameter determination. Because of the increased signal strength, the tissue compression method is useful in quantitating other blood constituents that do not absorb light as strongly as or are present in more dilute concentrations than the various species of hemoglobin. The tissue compression method may also be adapted to the use of more than one wavelength of light to quantitate more than one blood constituent.
  • blood glucose may be measured according to the above described theoretical considerations using at least one wavelength, for example, 9,700 nm. Since measuring blood glucose is difficult due to its weak light absorption characteristics and its dilute concentration in the blood, glucose determination may require one or more reference wavelengths for its measurement. Matrix algebra derivations solving for glucose imply that the additional wavelength needed for glucose concentration determination may be any wavelength that accurately measures some other blood constituent - hemoglobin, for instance. What this means is simply that once hemoglobin concentration has been determined from a system using one wavelength, the addition of a second, glucose-sensitive or other blood constituent-sensitive, wavelength allows accurate measurement of glucose or other constituent where it could not do so by itself.
  • Photometric Unit - comprising a laser diode or other hght emitting source (810 nm, 9700 nm, etc.), for example, filtered, collimated, ultra bright white light sources, and control circuitry, photodiode and signal conditioning circuitry and mounting hardware.
  • Tissue Compression Unit - comprising a mechanical linkage for effecting appropriate tissue compression kinematics, stepper motor and drive circuitry, linear actuator and associated hardware.
  • C. Precision Distance Measuring Unit - comprising, for example, linear variable differential transformer (LVDT), driving circuitry and mounting hardware.
  • LVDT linear variable differential transformer
  • Data Collection and Conditioning Unit - comprising, for example, a personal computer with multichannel analog to digital board for data filtering, amplification, conditioning for display, and storage.
  • a Force Measurement Unit strain gauges and bridge circuitry mounted to mechanical linkages for measuring tissue compressive forces and mechanical linkage deformations.
  • the noninvasive device to determine THb and Hct values based on the photometric methods explained above comprises five subunits with an optical sixth subunit.
  • the first is the photometric subunit comprised of, for example, a near isobestic point (810 nm) communications type laser diode (LT010MF, Sharp Corp., Osaka, Japan) with control circuitry (IR3C01 Sharp Corp., Osaka, Japan), or like light source capable of emitting light of the desired wavelength for a given chromophore to be measured, an integrated photodiode and amplifier circuit chip with signal conditioning circuitry
  • Light sources capable of creating a radiant energy source of wavelengths up to 11,000 nm are known in the art.
  • the tissue compression subunit comprises a four bar mechanical linkage for effecting tissue compression kinematics.
  • the opposing arms of this subunit move together along nearly parallel paths.
  • This linkage may be driven manually or by stepper motor with linear actuator (e.g., motor model P310.158 and linear gear box model LIO.100.01, Portescap US, Inc., 36 Central Ave., Hauppauge, NY) hardware and control circuitry.
  • linear actuator e.g., motor model P310.158 and linear gear box model LIO.100.01, Portescap US, Inc., 36 Central Ave., Hauppauge, NY
  • the precision distance measurement subunit comprises, for example, a linear differential variable transformer (LVDT) (model S300, Columbia Research Labs, Inc., 1925 MacDade Blvd.,
  • LVDT linear differential variable transformer
  • Woodlyn, PA 19094 with the core mounted to one arm of the tissue compression subunit and the transformer primary and secondary windings to the other arm and control circuitry.
  • any means for precisely measuring the comparison distance would be acceptable.
  • the data collection and conditioning unit Among the variables to be assimilated by the data collection and conditioning unit are the measurements of initial tissue thickness, tissue compression distance, photodiode signal strengths, tissue compression forces and time of compression. Time of compression is potentially important because non-blood tissue fluids are somewhat mobile, but not nearly so mobile as blood. In addition to measuring the necessary elements, it would also be desirable for the data collection unit for perform the necessary calculations as described above to provide a continuous readout of blood constituents.
  • a power supply subunit powers all the electronic signal conditioning circuits and drives the laser diode and the stepper motor.
  • the data collection subunit may comprise, for example, a Gateway2000 80486-based personal computer (Gateway2000, 610 Gateway drive, North Sioux City, SD) equipped with a 12 bit multichannel analog to digital converter board (model Dt2814, Data Translation, Inc., 100 Locke Drive, Marlborough, MA 01752) for acquiring signals.
  • a force measurement subunit may optionally be provided to measure compression forces and to allow monitoring at mechanical arm deformations upon actuation of the tissue compression unit.
  • the force measurement subunit can be incorporated so as to act as a safety interlock, interrupting power to the tissue compression unit as soon as a pre-set limit is exceeded.
  • the force measurement subunit also enables an operator of the device to enter calibration corrections to account for such known individual variable such as elevated blood pressure which may otherwise provide for an undesirable bias in the collected data.
  • the laser diode 1 and photodiode 2 forming the photometric unit are mounted behind glass, which may include polarizing filter, directly on the calipers of a micrometer.
  • the photometric unit is integral to the tissue compression unit, which in this case requires no stepper motor.
  • the precision distance measuring unit 3 is provided by the readout from the micrometer as the opposing jaws of the micrometer are used to compress an illuminated body part placed between the opposing jaws of the micrometer.
  • a data collection unit 4 comprising a signal conditioning (amplification and filtering) and a separate display unit, provides a readout of the hght intensity produced by the laser diode 1 and the amount of light received by the photodiode 2.
  • the power supply is shown as 5.
  • a source of radiant energy 1 a receiver of radiant energy 2, comprising the photometric unit.
  • the photometric unit is integral to the tissue compression unit, which further comprises a motorized pump platform 6 and a motor driven screw 7, for achieving precise compression of a tissue placed between the light source 1 and receiver 2.
  • the precise amount of compression produced by action of the motorized compression unit provided a precisely measured amount of linear distance change between the hght source 1 and detector 2, and this information is fed directly to a multi-channel data acquisition and controller system 4.
  • the tissue compression unit and precise distance measuring unit 3 of the invention are, in this embodiment of the invention, integral to each other.
  • a power source 5 is indicated, and the data collection unit 4 is exemplified as a two component unit comprising a multi-channel data acquisition and controller system and a personal computer which is capable of performing all the necessary calculations of light intensities detected and change in optical length to provide a continuous readout for any given wavelength/blood component.
  • force measurement unit 8 comprising a pressure transducer, is provided and can act as a power interrupt (interlock) to stop tissue compression if a pre-set pressure limit is exceeded.
  • Figure 9 exemplifies a preferred embodiment.
  • the radiant energy source (e.g., a laser diode) 1 and detector 2 are shown on opposing arms of the device, thereby forming an integral photometric unit/tissue compression unit.
  • the tissue compression unit is actuated by a stepper motor 9, which transmits tissue compression pressure to the photometric unit.
  • the amount of compression is measured by a linear variable differential transformer (LVDT) 3 which acts as the precision distance measuring unit.
  • LVDT linear variable differential transformer
  • the power supply which energizes the stepper motor, the LVDT, and the photometric unit, is not shown.
  • Strain gauges are provided as the force measurement unit with the previously described function of tissue compression interrupt.
  • the invention claimed here can be practiced with only one light source and a means of ⁇ V determinatioa Access to Sp0 2 output (obtained from any accurate source, such as a pulse oximeter) is required to calculate either THb and Hct, or Ca0 2 , depending upon the algorithm chosen.
  • the novel device can be built into a pulse oximeter; no additional hght source is required.
  • the component that determines ⁇ V is also supphed. The measurement of changes in mHb0 2 is then correlated to volume changes that are either passively measured or actively produced.
  • Example 2 Changes in the mass of oxyhemoglobin, total hemoglobin, and reduced hemoglobin molecules can be measured via absorption photometry using hght having a wavelength from between about 400 nm and about 1100 nm. Other blood components may be measured using wavelengths up to and including 11,000 nm. For example, a wavelength of about 660 nm can be used for direct Hb0 2 measurement ( Figure 2). Other wavelengths which can be utilized include 810 nm (direct THb determination, see Figure 3) and 940 nm (direct RHb measurement). These wavelengths of hght are sensitive to changes in mHb0 2 , mTHb, and mRHb, respectively.
  • the corrected AC signal can be extracted from a standard pulse oximeter. Alternatively, such a corrected AC signal could be readily obtained by a person skilled in the art utilizing standard equipment and photometric procedures. However, correction of the AC signal is not necessary in all applications.
  • the AC or DC signal can be used in the algorithm where THb is measured directly
  • the desired DC or AC signal is then used to calculate ⁇ mHb0 2 .
  • mHb0 2 is measured directly, for example, this can be done by generating a calibration curve which relates change of mHb0 2 to changes in 660 nm corrected AC signal amplitude.
  • ⁇ mHb0 2 can be determined indirectly with the DC signal from an 810 nm hght source.
  • THb is measured directly and with Sp0 2 , ⁇ mHb0 2 is then calculated using equation (2).
  • Ohmeda 3700 (Ohmeda, Boulder, CO) pulse oximeters are accurate to within 7% of their displayed saturations (Cecil, W.T., K.J. Thorpe, E.E. Fibuch, and G.F. Tuohy [1988] J. Clin. Monit. 4(1):31- 36).
  • hght source Although only a single hght source is needed in most adult patients, more than a single light source can also be employed. Indeed, additional light sources may be useful in determining Ca0 2 in circumstances where other hght-absorbing hemoglobin species are present.
  • Measurement of other hght-absorbing blood constituents may also require additional hght sources to optimize the measurement accuracy. Determination of the proper wavelength to be used for measuring various blood constituents is within the skill of those trained in this field.
  • any type of energy which can be measured and used to quantitate blood constituents may be used to practice the subject invention.
  • any form of electromagnetic radiation, sound wave, or magnetic property which can be used to trans-irradiate a body part can be utilized so long as the characteristics of the energy are altered by the relevant blood constituents and so long as these changes can be measured and correlated with changes in blood volume.
  • NIBP noninvasive blood pressure
  • This commercially available device rapidly pressurizes and depressurizes the bladder to maintain the finger surrounded by the bladder at nearly constant volume during the pulse.
  • the pressure changes in the bladder can be correlated to volume changes in the finger utilizing standard gas law calculations. These calculations take into account original bladder volume, gas temperature, change in bladder volume and compliance of the bladder.
  • a second approach for determining volume changes is to measure changes in the length of the light path between the light source and photodetector. Then the volume is approximated by modelling the hght path.
  • this model can be a cylinder between emitter and detector with a cross-sectional area equal to the receptive field of the photodetector.
  • Measurements or changes in volume can be made passively or actively. Passive measurement would involve, for example, measuring the actual finger expansion and contraction with each pulse. We have been able to show that finger volume does change with each pulse.
  • the finger was placed into a closed rigid chamber (syringe plunger port) filled with an incompressible fluid (water).
  • a pressure transducer (Datascope P3 Module interfaced with a Datascope 870 Monitor, Datascope Corp., Paramus, NJ) was primed with water and connected to the syringe tip. A pulsatile pressure wave form was obtained and reproduced. This provides evidence that the finger does indeed experience volume changes with blood pulsation.
  • Measurement of actively produced volume changes can also be utilized. Active measurement results from compression and release of tissue at the measurement site by a known distance. If the hght source and the photodetector are brought closer together by an external force, e.g., a motor, which produces a volume change in the receptive field, the same data can be obtained.
  • an external force e.g., a motor
  • This method requires some amount of Hb0 2 to be displaced from the receptive field.
  • This procedure can result in the measurement of larger changes in volume compared to passive measurements of volume change during a pulse. Measuring larger volume changes can advantageously reduce experimental error during measurement.
  • the device and method of the subject invention can be utilized in conjunction with life support systems and other medical instrumentations.
  • the subject invention can be used as a sensor for a continuous automatic feedback loop that is designed to maintain Ca0 2 and/or THb or Hct.
  • An infusion pump, ventilator, and or anesthesia machine can be controlled by the sensor.
  • the sensor would enable the system to maintain levels of CaO, and/or THb/Hct at levels which are predetermined by the operator of the system.
  • Example 10 The wavelength and source of Hght employed in the design of the invention can be optimized by those skilled in the art, depending on the particular application. Thus, if direct mHb0 2 determination is desired, an approximately 660 nm light source can be utilized. If, however, direct mTHb determination is desired, a wavelength near the isobestic point of 805 nm (e.g., 810 nm) can be employed. If direct determination of RHb is sought, a light wavelength near 940 nm can be used. With any of these wavelengths, the remaining unknown parameters (THb and/or Hct and/or RHb and or Ca0 2 ) can be determined indirectly with the addition of an accurate Sp0 2 value using the various formulae discussed above.
  • THb and/or Hct and/or RHb and or Ca0 2 the remaining unknown parameters
  • the light can be from an LED and/or laser source, such as a laser diode.
  • the laser offers advantages over an LED because its emission spectra is much narrower, its power attenuation with increasing distance is small in comparison, its output is more directional and it is a more ideal beam Thus, reproducibihty and confidence are improved. These advantages allow for easier modeling and subsequent implementation of applications where the distance between hght source and receiver changes. If a laser or other hght emitting source is utilized, the use of fiber-optic technology may also be employed. Fiber-optic cables allow the somewhat motion-, temperature-, and current-sensitive laser or other hght emitting source and detector elements to remain protected and remote from the patient, and also provide an extremely high degree of electrical isolation between the patient and the device.
  • Noise consists of the background hght that enters the photovoltaic cell (PVC) and alters the signal output.
  • Polarizing films can be employed to reduce the effects of background scattered hght. This is achieved by placing a polarizing film in a known orientation between the emitter and tissue and another film in an identical orientation between the tissue and receiver. This configuration prevents randomly polarized hght from entering the PVC. As a consequence, scattered hght from the emitter, as well as ambient light that is rotated with respect to the orientation of the polarizing film, is filtered from the PVC input. All photoplethysmographic devices, including pulse oximeters, would benefit from this application.
  • polarizing films in this fashion has the added advantage of essentially defining a volume of tissues of similar cross-sectional area to the PVC.
  • the volume's length is the linear distance between emitter and detector. Hence, volume determination is simplified.
  • “Active" volume determination requires a physical displacement of the emitter relative to the PVC. This displacement can be mechanically limited to a known distance. It can also be limited by the tissue pressure upon one of the device elements (i.e., the PVC or light source), or by a combination of pressure and displacement.
  • the method of actively varying volume can be applied equally well to the new pulse oximeter technologies that employ reflectance or backscatter of hght for their signals. If one varied the slab length, width, or depth from which they receive their signals, essentially a volume change would have been made and similar algorithms to those described above would apply. Therefore, SpOj, THb, HbO,, RHb, Ca0 2 and local oxygen consumption could each be determined using these new technologies.
  • the claimed device can also be used to determine interstitial fluid content, or state of hydration.
  • Such a device would be beneficial in the clinical assessment of delirium, hypotension, tachycardia, and other medical conditions.
  • critical care settings e.g., emergency rooms
  • chronic care settings e.g., nursing homes.
  • the no ⁇ 'el device of the subject invention operates by measuring changes in signal strength that occur after a rapid compression (or decompression) of a tissue.
  • the tissue can be thought of as a two compartment system: the intravascular compartment that contains blood and the interstitial compartment that contains body water.
  • a hydrostatic pressure change is applied. Since the fluid cannot shift instantaneously between compartments, it shifts first within the compartment with the least resistance to flow.
  • the interstitial fluid is impeded from making rapid shifts because it is trapped in tissue planes and held within the interstitial compartment by hydrophihc molecules.
  • the blood within the intravascular compartment is capable of making rapid shifts.
  • the measured signal varies with the mass of absorber (i.e., mass of Hb0 2 , RHb, or THb, depending on the wavelength used) in the light path. As reasoned above, after rapid (de)compression, the signal can be expected to vary in a fashion that is related to hydration status.
  • a backscatter oximeter may be used to determine mixed venous O 2 content in the superficial jugular vein while Ca0 2 is determined at a peripheral site. Such a combination may provide a good solution to the Fick equation for cardiac output.
  • Another example of a new application is to combine the algorithms that directly determine mTHb and mHbO 2 by the new method and design an entirely new pulse oximeter based on measuring vascular volume changes.
  • LT010MF weU collimated laser diode
  • the laser diode module included a control chip (IR3C01 Sharp Corp., Osaka, Japan) to maintain stable power output.
  • the photodiode signal was transmitted by shielded cable to a signal conditioning unit for current to voltage conversion, amplification and filtering. The signal amplitude was then read off from a digital volt meter.
  • a mongrel dog was anesthetized with a barbiturate infusion. Data were collected by placing the dog's tongue between the glass slides of the caliper assembly and observing voltage readings with the tissue both uncompressed and compressed A block of material was mounted on the caliper slide to determine caliper excursions during compression. THb values were incrementally lowered by intravenous administration of a 0.9% saline solution. After each ad ⁇ nnistration of saline, blood was drawn and THb determined by CO-Oximeter (model IL-282, Instrument Laboratory, Lexington, MA). Photodiode signal measurements were taken with the tongue in uncompressed and compressed states.
  • the device shown in Figure 7 It was constructed from a motorized infusion pump. Again, the laser diode and the photodiode were mounted on opposing arms of the device, behind glass slides. The new device was used to compress finger tip tissue side- to-side and measure photodiode output. Data from five Caucasian and two African American volunteers were taken with tissue compression distances of 2.0 and 2.5 mm. THb values were determined from drawn blood samples by the CO-Oximeter as in the dog study.

Abstract

Described here are a novel means and device for noninvasively quantifying important blood constituents. Total hemoglobin, arterial oxygen content, hematocrit, and other parameters can all be determined quickly and easily without the need for skin puncture or lengthy laboratory analysis. The invention described here concerns the simultaneous measurement or control of volume changes and changes in the mass of either oxyhemoglobin, total hemoglobin, or reduced hemoglobin or other blood constituents such as glucose, bilirubin or cholesterol. The data obtained by these measurements is used to quantify the parameters of interest.

Description

DESCRIPTION
METHOD FOR NONINVASIVE INTERMITTENT AND/OR CONTINUOUS HEMOGLOBIN. ARTERIAL OXYGEN CONTENT. AND HEMATOCRIT DETERMINATION
Cross-Reference to a Related Application This application is a continuation-in-part of our co-pending application Serial No. 08/052,806, which was a continuation of Serial No. 07/864,883, which was a divisional of our application Serial No. 07/368,636, now U.S. Patent No. 5,101,825, which was a continuation-in-part of our application Serial No. 07/264,119, filed October 28, 1988, now abandoned.
Background of the Invention Arterial oxygen content was once assessed relying only on physical signs and symptoms such as cyanosis, tachypnea, bradycardia, tachycardia, dyspnea, and shortness of breath. Today, devices exist which allow accurate and rapid quantitative measurement of arterial oxygen content.
Partial pressure of oxygen (P02) in blood, percent hematocrit (Hct), percent arterial hemoglobin saturation (SaOj), gram-percent total hemoglobin (THb), and arterial oxygen content (Ca02) are all readily available to the physician in modern hospitals. Unfortunately, however, measurement of these variables has until recently always required an invasive arterial puncture or phlebotomy. Once the whole blood sample is obtained, analysis is accomplished using spectrophotometric and chemical means.
During the early 1970's, the first pulse oximeter was introduced. This device permitted approximation of Sa02, termed Sp02, by noninvasive means. The design was subsequently improved upon and the current generation of pulse oximeters is now commonplace in the intensive care unit (ICU), emergency room (ER), operating room (OR), and recovery room (RR).
Pulse oximeter design is well documented. It utilizes two light-emitting diodes (LED). Each
LED emits a specific wavelength of light that is transmitted through the tissues to a photodetector.
These wavelengths are chosen to be around 660 nm (red spectrum) and around 940 nm (near- infrared spectrum) because of the absorbency characteristics of oxyhemoglobin (Hb02) and reduced hemoglobin (RHb). An electrical signal consisting of two components is generated by the photodetector receiving the LED emission. There is an invariant direct current (DC) component to the signal which represents ambient background light and transmission of light through invariant, that is, nonpulsatile tissues such as skin, bone, and, to a certain extent, veins. The second component of the signal is an alternating current (AC) which represents the varying transmission of light through the pulse-varying tissues, i.e., the arteries and capillaries. Both the AC and DC components are affected by altered LED light intensity. The AC signals must be corrected for inter-LED light intensity differences prior to their use for SpO, calculation. A pulse oximeter does this by dividing each LED's AC signal by its corresponding DC signal to produce the "corrected" or "normalized"
AC signal. The terms "corrected" and "normalized" are used synonymously herein when referring to this procedure. The ratio of the corrected AC signal at 660 nm to that at 940 nm is compared to a stored calibration curve that yields Sp02. Thus, to calculate Sp02, a pulse oximeter generates a corrected AC signal for both LED wavelengths. At this time, determination of the other variables, such as methemoglobin (MetHb), Hct,
THb, Ca02, continues to require arterial puncture or phlebotomy. Skin puncture procedures are painful to the patient, time consuming, and provide opportunities for infection. There is a great need for a rapid and accurate noninvasive means of assessing THb, Ca02, and Hct. Such an assessment means would enable the health care provider to quickly evaluate and follow a patient's circulating blood status. Questions of hemodilution during volume expansion in the field, ER, ICU, and OR would be rapidly answered. Hemoconcentration after blood transfusion, hemodialysis or bone marrow transplantation could be followed without repeated venipuncture. Furthermore, many "routine" screening phlebotomies to assess THb and Hct such as for preoperative laboratory studies in children and adults could be eliminated.
Brief Summary of the Invention The subject invention concerns a novel means and device for noninvasive determination of total hemoglobin, arterial oxygen content, and hematocrit. Advantageously, these determinations can be made intermittendy and/or continuously. The novel procedure described here is painless and eliminates the need for skin punctures. It is cost effective because there is no need for needles, syringes, gloves, bandages, or skilled technicians. Advantageously, critical data can be obtained in seconds rather than minutes or hours and continuously rather than episodically.
The determination of the blood parameters of interest is accomplished by measuring the change in the mass of hemoglobin (Hb02, RHb, or THb) resulting from a measured or controlled change in volume of blood Each of these two measurements or controlled changes can be achieved noninvasively. For example, the change of mass of hemoglobin species associated with a controlled change in volume can be measured photometrically by passing light of appropriate wavelength(s) through a portion of the body. The attenuation of the light which can be detected by a photometer is related to the amount of hemoglobin species in the blood being analyzed. When changes occur in the volume or hemoglobin species concentration of blood being analyzed, corresponding changes in the mass of hemoglobin species can be measured. There are several noninvasive means which can be used to measure or control changes in blood volume in the portion of the body being analyzed.
Once these measurements have been made, the blood parameters of interest can be readily calculated.
Brief Summary of the Figures Figure 1 is a schematic representation of one embodiment of the invention where Hb02 is measured directly and a pulse oximeter is utilized.
Figure 2 is a schematic representation of one embodiment of the invention where Hb02 is measured directly and a pulse oximeter is not explicitly incorporated.
Figure 3 is a schematic representation of one embodiment of the invention where THb is measured directly and a pulse oximeter is not explicitly incorporated.
Figure 4 is a schematic representation of one embodiment of the invention where desired hemoglobin species is/are measured and a pulse oximeter is not explicitly incorporated.
Figure 5 is a diagram of the Caliper-mounted device for collection of dog data.
Figure 6 is dog data total hemoglobin (g/dL) versus ln(VJV])/Del-X (mm*1).
Figure 7 is a diagram of the device used for collecting human data.
Figure 8 is data of human population total hemoglobin (g/dL) versus lnCVJVJ/Del-X (mm'
')•
Figure 9 is a data collection device.
Detailed Description of the Invention Oxygen content in arterial blood can be calculated using the formula:
Ca02(mL 02/dL) = THb(g dL) x Sa02 x 1.39(mL 02/g Hb02), (1) where Sa02 is a fraction (Hb02/THb). Oxyhemoglobin (Hb02) is the oxygen carrying species of THb and can be calculated,
Hb02(g/dL) = THb Sa02. (2)
Substituting Equation (2) into Equation (1),
Ca02(mL O^dL) = Hb02(g/dL) x 1.39(mL 02/g Hb02). (3)
It becomes apparent that oxygen content can be calculated if oxyhemoglobin is known. Therefore, if the mass of oxyhemoglobin molecules [mHb02(g)] in a given volume [V(dL)] is known, the oxygen content of that volume can be determined. Stated another way, if a change in the mHb02 can be measured along with the corresponding change in volume, oxygen content can be measured. This relationship can be written
Hb02(g/dL) = [mHb02t2 _ mHbOai ]/[Vt2 - Vu], (4)
where subscripts tl and t2 represent two points in time. This can be rewritten as
Hb02 = ΔmHbO^ΔV, (5)
where ΔmHbO, is the change in mass of the HbO, species and Δ V is the measured corresponding change in volume. The value for ΔmHb02, if mHb02 is measured directly, can be calculated using a signal generated by a pulse oximeter, for example. mHb02 can also be determined indirectly. Indirect determination requires accurate Sp02 and either RHb or THb values. Sa02 and Sp02 are known to be close to each other. If RHb and Sp02 are known, then
RHb = THb x [(100-SpO2)/100], (6)
and solving for THb yields
THb = (RHb x 100)/(100-SpO2). (7) Substituting equation (7) into
Hb02 = THb-RHb, (8)
one obtains:
Hb02 = [(RHb x 100)/(100-Spθ2)]-RHb. (9)
If THb and Sp02 are measured, Equation (2) can be utihzed for indirect mHb02 determination and equation (8) will then permit calculation of RHb.
The invention can be practiced utilizing Equations (4) and (5). The same equations may be used for any hemoglobin species, e.g. for THb, using a wavelength of 810 nm. These equations are clinically useful approximations of the pertinent biological phenomena to be measured by the subject invention. Additional terms can be added to Equations (4) and (5). These additional terms reflect the relatively small effects which are attributable to respiration and other physiological activities.
These effects can be extracted and utilized for analysis of respiration and other clinically-relevant parameters.
Once ΔmHb02 is calculated, completion of the Ca02 calculation requires determination of ΔV (Eqn. 5). This can be accomplished in numerous ways. Thus, Ca02 is calculated in real-time by one of several similar algorithms entirely through noninvasive means. If the algorithm solving directly for ΔmHb02 is used, THb can be calculated using the Sp02 output from another device, such as the pulse oximeter, with the equation
THb(g/dL) = Ca02(mL 02/dL)/[Sp02 x 1.39(mL 02/g Hb02)]. (10)
Of course, if the light source from a pulse oximeter is used to obtain ΔmHb02, then Sp02 from that same pulse oximeter, or similar device, can be utihzed (Figure 1).
Hct can be estimated from either Ca02 or THb using additional calibration curves. Most commonly, Hct is well approximated by multiplying THb by a factor of three. For example, if a patient has a Ca02 = 20 mL OJdL at Sp02 = 100% and a THb = 15 g/dL (i.e., 15 gram-percent), one can estimate that with normal red blood cell (RBC) morphology Hct is near 45%. If THb is reduced, a proportional Hct change can be anticipated. If one has prior knowledge of RBC morphology, for example, that the RBC's are macrocytic or microcytic, then this can be entered into the monitor and an appropriate calibration curve used. The claimed device comprises a small appliance that is easily attached to the patient. For example, the device can be attached onto the finger, earlobe, wrist, lips, nares, tongue, cheek, or some other site. The device further comprises a signal processing part that also displays the results.
The device displays Ca02, THb, and an estimate of Hct continuously or intermittently. Theoretically, MetHb, and Carboxy Hb (COHb), glucose, bilirubin, etc. can also be quantified.
Although Sp02 input to the device is required for calculation of THb with two of the algorithms, the device does not necessarily require incorporation into a pulse oximeter, or similar device, to determine THb. Instead, an Sp02 value can be obtained via the digital output port of a pulse oximeter, or similar device, and input into the proposed device. Thus, the device could be incorporated into a pulse oximeter (or similar device), as illustrated in Figure 1, or operate as a unit distinct from it as diagrammed in Figures 2, 3 and 4.
While the measurements for quantitating THb may be conducted by measuring volume changes in illuminated tissues, the signal may be amplified, and individual tissue differences may be reduced, by employing a volume change control means. This embodiment of the invention, including its theoretical basis and practical implementation, are described below. Example 17 provides in vivo results obtained using this embodiment of the invention. In addition, the extension of this method to monitoring of other relevant blood constituents, besides hemoglobin, such as glucose, bilirubin or cholesterol, is also described.
Efforts to use nonpulsation photometric methods to measure light absorbing blood constituents and related parameters have all been hampered by the fact that light absorption and optical path length through nonblood tissues differ from person to person and that the optical path lengths through the blood itself are unknown. Pulsation methods like pulse oximetry which can eliminate these factors are generally limited to determining ratios of blood constituents and further limited by the fact that naturally pulsating blood gives a very low signal. This signal, typically measured by photodiode as a time varying (AC) signal superimposed on a large constant (DC) value, is generally only about 1% of the DC value. What is more, AC signal strengths are dependent on tissue perfusion which depends on such things as blood pressure, vascular condition, temperature and blood pressure arm cuff cycling. Blood constituents that do not absorb light as strongly or are of more dilute concentration as the various species of hemoglobin provide even weaker photometric signals. As a result, there remains a need to provide a more sensitive method for measuring these parameters which is less susceptible to noise and inter-individual variations. By measuring or controlling volume changes through tissue compression, this goal is realized.
The theory underlying our tissue compression method for deterniining THb and other blood constituents in vivo is similar to pulse oximetry theory. The compression method differs from pulse oximetry in that actual concentrations of hemoglobin (or other light absorbing constituents such as glucose, bilirubin or cholesterol) may be determined.
It is reasonable to think of living tissue as being comprised of three compartments that behave differently under compression. The first and most mobile compartment is blood. As tissue is compressed, arterial, venous and capillary blood readily leaves the tissue because it is mobile.
This is easily demonstrated by pinching the fingernail bed and observing that it blanches as blood exits the tissue. When pressure is released, the blood quickly returns. The next most mobile compartment is interstitial fluid, trapped within tissue planes and adsorbed to hydrophilic molecules. These fluids migrate out of the tissue at a much slower rate. The third compartment consists of immobile, sohd tissues.
In blood, the major light absorbers are species of hemoglobin: RHb, Hb02, COHb and metHb. COHb typically comprises 3% to 5% of all hemoglobin and as much as 10% to 15% in smokers. MetHb is typically less than 1% of the total except in rare disease states. The remaining hemoglobin is primarily split between RHb and Hb02, depending on blood oxygen saturation. Not only are extinction coefficients different for each of these species, but the coefficients vary with wavelength of light.
The photometric measurement of blood constituents is described by the Beer-Lambert law in which colliniated light travels through a uniform light absorbing medium:
ln(IJI0) = - K C L (11)
where is the light source intensity as it enters the medium, Ij is the light intensity emerging from the absorbing medium, K is a proportionally constant called the "extinction coefficient" which describes the characteristics of the substance in the medium that absorbs light, C is the concentration of the light absorbing substance and L is the optical path length through which the light passes. For more than one light absorber in the medium, the equation becomes:
lnαΛ) = -(K, Ci + K2 C, + K3 C3 + . . .)L, (12)
where the numerical subscripts for K and C indicate extinction coefficients and concentrations for light absorbers numbered 1, 2, 3 etc. The optical path length L, is assumed to be the same for all absorbers.
Modifying the Beer-Lambert relation in equation (12) for the two light absorbers Hb and Hb02 gives the relation: ln(I,) - In^) = -(KH,, Cm, + KHb02bcs)^, - Kτ Cr LT (13)
where K^,, Km^ and Kτ are extinction coefficients for RHb, Hb02, and nonblood tissues and Cm,, 0^02 and Cf are concentrations of RHb, Hb02 and the light absorbing substances in the nonblood tissues, respectively. The subscript "1" indicates that measurements are made at a first point in time.
Optical path lengths are designated as Lβ, through blood and L-- through nonblood tissues.
Equation (13) may be duplicated for a second point in time, designated by the subscript "2", at which point the optical path length through the blood is different than at the first point in time:
ln 2) - ln(I0) = -(KHb CHb + KHbO2 CHbo2)LB2 - Kτ Cτ Lτ (14)
Note that the only changes from (13) to (14) are that Lg, changes to l_2 and I, to I2. Subtracting equations (13) and (14) accomplishes three things. First, the light source intensity , is eliminated. Thus, lo need not be measured. Second, the last terms of equations (13) and (14) that account for nonblood tissues are also eliminated so that person-to-person differences need not be known. This second item is what makes it possible for our method and device to work on the general population without the need for individual calibration. Third, only the ratio of the variables I2 and I, needs to be known and not their actual values. This means that measurement calibration for actual light intensity is not necessary. The equation that results from the subtraction is as follows:
In (I2/I,) = (Ka, C__ + K^ C^A ,, (15)
where ΔLβ = (L_ - L__).
A simplified model comprises hght passing from a source on one side of a volume of living tissue to a detector on the other side. The blood and less mobile nonblood tissues occupy separate and distinct compartments. As the tissue is compressed, the optical path length through blood decreases while the path length through nonblood tissues is unchanged. Thus, the term ΔLβ in equation (15) is due entirely to changes in the blood optical path length. If the actual value of ΔLB is known, then the only unknown values left in equation (15) are the concentrations of RHb and Hb02 (i.e., C^ and Cm^, respectively).
Using the isobestic wavelength where RHb and Hb02 absorb hght equally (i.e., then- extinction coefficients are identical) these two unknowns can be reduced to only one unknown, the concentration of total hemoglobin (Crπb or simply THb). This isobestic point occurs at a wavelength of 805 nm At the isobestic point, the extinction coefficient of COHb is also very small relative to Hb and Hb02 so that the resulting value of THb includes the concentrations of these functional hemoglobin species but is not affected by the nonfunctional species COHb. While metHb is a strong absorber at 805 nm., it is present in very low concentrations and will have no appreciable effect on the THb value. With isobestic hght, equation (15) becomes:
to(I2/I1) = K1Ηb CTHb ΔLB (16)
which can be solved for C__ as follows:
THb = C1Hb = ln(I2/I1) / (Krab ΔLB) (17)
Since the ratio of I2 to I, is measured, K^ is an empirically determined constant and ΔLβ is measured or controlled by the device that compresses the tissue, THb may be calculated.
Thus, all that is required is that the initial and final hght intensities be measured, the constant K__ (or any other blood parameters empirically determined constant) and a known change in the optical path produced by a volume control (tissue compression) means to adjust the separation between the light emitter and detector.
The tissue compression method described here may be used to determine actual blood constituent concentrations instead of just ratios of concentrations like the pulse oximeter does. Since the method involves compressing tissues to change the optical path length through blood, the optical path length change is controlled and not dependent on the variability of natural pulsations, as in pulse oximetry. Thus, large signals on the order to 10% to 40% of the DC value are possible on demand with consequent improvements in signal to noise ratio and accuracy of blood parameter determination. Because of the increased signal strength, the tissue compression method is useful in quantitating other blood constituents that do not absorb light as strongly as or are present in more dilute concentrations than the various species of hemoglobin. The tissue compression method may also be adapted to the use of more than one wavelength of light to quantitate more than one blood constituent.
Accordingly, all of the foregoing considerations may be applied to measurement of blood chromophores having light absorption maxima up to and including 11,000 nm. As a specific example, blood glucose may be measured according to the above described theoretical considerations using at least one wavelength, for example, 9,700 nm. Since measuring blood glucose is difficult due to its weak light absorption characteristics and its dilute concentration in the blood, glucose determination may require one or more reference wavelengths for its measurement. Matrix algebra derivations solving for glucose imply that the additional wavelength needed for glucose concentration determination may be any wavelength that accurately measures some other blood constituent - hemoglobin, for instance. What this means is simply that once hemoglobin concentration has been determined from a system using one wavelength, the addition of a second, glucose-sensitive or other blood constituent-sensitive, wavelength allows accurate measurement of glucose or other constituent where it could not do so by itself.
In practical terms, the foregoing theoretical considerations are implemented by a device having the following constituent parts:
A. Photometric Unit - comprising a laser diode or other hght emitting source (810 nm, 9700 nm, etc.), for example, filtered, collimated, ultra bright white light sources, and control circuitry, photodiode and signal conditioning circuitry and mounting hardware.
B. Tissue Compression Unit - comprising a mechanical linkage for effecting appropriate tissue compression kinematics, stepper motor and drive circuitry, linear actuator and associated hardware. C. Precision Distance Measuring Unit - comprising, for example, linear variable differential transformer (LVDT), driving circuitry and mounting hardware.
D. Data Collection and Conditioning Unit - comprising, for example, a personal computer with multichannel analog to digital board for data filtering, amplification, conditioning for display, and storage. E. Power Supply - to provide electrical power for driving electrical circuits and the stepper motor.
Optionally, a Force Measurement Unit - strain gauges and bridge circuitry mounted to mechanical linkages for measuring tissue compressive forces and mechanical linkage deformations. These components are next described in greater detail. The noninvasive device to determine THb and Hct values based on the photometric methods explained above comprises five subunits with an optical sixth subunit. The first is the photometric subunit comprised of, for example, a near isobestic point (810 nm) communications type laser diode (LT010MF, Sharp Corp., Osaka, Japan) with control circuitry (IR3C01 Sharp Corp., Osaka, Japan), or like light source capable of emitting light of the desired wavelength for a given chromophore to be measured, an integrated photodiode and amplifier circuit chip with signal conditioning circuitry
(e.g., OPT201, Burr-Brown Corporation, Tucson, AZ) and mounting hardware. Light sources capable of creating a radiant energy source of wavelengths up to 11,000 nm are known in the art.
The tissue compression subunit comprises a four bar mechanical linkage for effecting tissue compression kinematics. The opposing arms of this subunit move together along nearly parallel paths. This linkage may be driven manually or by stepper motor with linear actuator (e.g., motor model P310.158 and linear gear box model LIO.100.01, Portescap US, Inc., 36 Central Ave., Hauppauge, NY) hardware and control circuitry.
The precision distance measurement subunit comprises, for example, a linear differential variable transformer (LVDT) (model S300, Columbia Research Labs, Inc., 1925 MacDade Blvd.,
Woodlyn, PA 19094) with the core mounted to one arm of the tissue compression subunit and the transformer primary and secondary windings to the other arm and control circuitry. However, any means for precisely measuring the comparison distance would be acceptable.
Among the variables to be assimilated by the data collection and conditioning unit are the measurements of initial tissue thickness, tissue compression distance, photodiode signal strengths, tissue compression forces and time of compression. Time of compression is potentially important because non-blood tissue fluids are somewhat mobile, but not nearly so mobile as blood. In addition to measuring the necessary elements, it would also be desirable for the data collection unit for perform the necessary calculations as described above to provide a continuous readout of blood constituents.
A power supply subunit powers all the electronic signal conditioning circuits and drives the laser diode and the stepper motor. The data collection subunit may comprise, for example, a Gateway2000 80486-based personal computer (Gateway2000, 610 Gateway drive, North Sioux City, SD) equipped with a 12 bit multichannel analog to digital converter board (model Dt2814, Data Translation, Inc., 100 Locke Drive, Marlborough, MA 01752) for acquiring signals.
Additionally, a force measurement subunit may optionally be provided to measure compression forces and to allow monitoring at mechanical arm deformations upon actuation of the tissue compression unit. The force measurement subunit can be incorporated so as to act as a safety interlock, interrupting power to the tissue compression unit as soon as a pre-set limit is exceeded. The force measurement subunit also enables an operator of the device to enter calibration corrections to account for such known individual variable such as elevated blood pressure which may otherwise provide for an undesirable bias in the collected data.
Although the strength of light measured through the tissue from the laser diode source is generally quite strong, there is a potential for error being introduced from ambient hght levels. This is also a problem with pulse oximetry that is usually handled by "chopping" the light source (i.e., cycling them rapidly on and off) so that ambient light levels may be measured during off period. The ambient hght levels are then subtracted from the hght levels with the laser diode to obtain a value that does not include the ambient light. Since the laser diode selected was designated for communications use, it is capable of operation from DC to hundreds of megahertz. According to the foregoing description, one simple embodiment of this invention is shown schematically in Figure 5. The laser diode 1 and photodiode 2 forming the photometric unit are mounted behind glass, which may include polarizing filter, directly on the calipers of a micrometer. Thus, the photometric unit is integral to the tissue compression unit, which in this case requires no stepper motor. The precision distance measuring unit 3 is provided by the readout from the micrometer as the opposing jaws of the micrometer are used to compress an illuminated body part placed between the opposing jaws of the micrometer.
A data collection unit 4, comprising a signal conditioning (amplification and filtering) and a separate display unit, provides a readout of the hght intensity produced by the laser diode 1 and the amount of light received by the photodiode 2. The power supply is shown as 5.
In a different embodiment of this invention, shown in Figure 7, there is provided a source of radiant energy 1, a receiver of radiant energy 2, comprising the photometric unit. Once again, the photometric unit is integral to the tissue compression unit, which further comprises a motorized pump platform 6 and a motor driven screw 7, for achieving precise compression of a tissue placed between the light source 1 and receiver 2. The precise amount of compression produced by action of the motorized compression unit provided a precisely measured amount of linear distance change between the hght source 1 and detector 2, and this information is fed directly to a multi-channel data acquisition and controller system 4. Thus, the tissue compression unit and precise distance measuring unit 3 of the invention are, in this embodiment of the invention, integral to each other. A power source 5 is indicated, and the data collection unit 4 is exemplified as a two component unit comprising a multi-channel data acquisition and controller system and a personal computer which is capable of performing all the necessary calculations of light intensities detected and change in optical length to provide a continuous readout for any given wavelength/blood component. In addition, force measurement unit 8 comprising a pressure transducer, is provided and can act as a power interrupt (interlock) to stop tissue compression if a pre-set pressure limit is exceeded.
As an additional embodiment of a data collection device, Figure 9 exemplifies a preferred embodiment. The radiant energy source (e.g., a laser diode) 1 and detector 2 are shown on opposing arms of the device, thereby forming an integral photometric unit/tissue compression unit. The tissue compression unit is actuated by a stepper motor 9, which transmits tissue compression pressure to the photometric unit. The amount of compression is measured by a linear variable differential transformer (LVDT) 3 which acts as the precision distance measuring unit. For simplicity of representation, the power supply, which energizes the stepper motor, the LVDT, and the photometric unit, is not shown. Strain gauges are provided as the force measurement unit with the previously described function of tissue compression interrupt.
The foregoing principles and device were tested and in vivo data gathered as further reported below in Example 17.
Following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.
Example 1
The invention claimed here can be practiced with only one light source and a means of Δ V determinatioa Access to Sp02 output (obtained from any accurate source, such as a pulse oximeter) is required to calculate either THb and Hct, or Ca02, depending upon the algorithm chosen. In one embodiment, the novel device can be built into a pulse oximeter; no additional hght source is required. The component that determines ΔV is also supphed. The measurement of changes in mHb02 is then correlated to volume changes that are either passively measured or actively produced.
Example 2 Changes in the mass of oxyhemoglobin, total hemoglobin, and reduced hemoglobin molecules can be measured via absorption photometry using hght having a wavelength from between about 400 nm and about 1100 nm. Other blood components may be measured using wavelengths up to and including 11,000 nm. For example, a wavelength of about 660 nm can be used for direct Hb02 measurement (Figure 2). Other wavelengths which can be utilized include 810 nm (direct THb determination, see Figure 3) and 940 nm (direct RHb measurement). These wavelengths of hght are sensitive to changes in mHb02, mTHb, and mRHb, respectively.
The corrected AC signal can be extracted from a standard pulse oximeter. Alternatively, such a corrected AC signal could be readily obtained by a person skilled in the art utilizing standard equipment and photometric procedures. However, correction of the AC signal is not necessary in all applications. The AC or DC signal can be used in the algorithm where THb is measured directly
(Figure 4) using 810 nm light.
The desired DC or AC signal is then used to calculate ΔmHb02. In the embodiment where mHb02 is measured directly, for example, this can be done by generating a calibration curve which relates change of mHb02 to changes in 660 nm corrected AC signal amplitude. ΔmHb02 can be determined indirectly with the DC signal from an 810 nm hght source. THb is measured directly and with Sp02, ΔmHb02 is then calculated using equation (2).
There are a number of commercially available pulse oximeters which are capable of supplying the desired AC and/or DC signal. Additionally, these devices can be used to obtain accurate Sp02 input values. For example, the Nellcor N-100 (Nellcor, Inc., Hayward, CA) and
Ohmeda 3700 (Ohmeda, Boulder, CO) pulse oximeters are accurate to within 7% of their displayed saturations (Cecil, W.T., K.J. Thorpe, E.E. Fibuch, and G.F. Tuohy [1988] J. Clin. Monit. 4(1):31- 36). The Datascope ACCUSAT (Datascope Corp., Paramus, NJ) and the Ohmeda 3700 pulse oximeters display saturation within 2.4% of actual Sa02 (Mendelson, Y. J.C. Kent, A. Shahnarian, G.W. Welch, and R.M. Giasi [1988] J. Clin. Monit. 4(l):59-63). Regression analysis shows these products have high correlation coefficients with small standard error of estimate (r=0.99, SEE=1.29% and r=0.99, SEE=1.72% for the Datascope ACCUSAT and Ohmeda 3700, respectively).
Example 3
Although only a single hght source is needed in most adult patients, more than a single light source can also be employed. Indeed, additional light sources may be useful in determining Ca02 in circumstances where other hght-absorbing hemoglobin species are present.
Measurement of other hght-absorbing blood constituents may also require additional hght sources to optimize the measurement accuracy. Determination of the proper wavelength to be used for measuring various blood constituents is within the skill of those trained in this field.
Example 4
Any type of energy which can be measured and used to quantitate blood constituents may be used to practice the subject invention. Thus, any form of electromagnetic radiation, sound wave, or magnetic property which can be used to trans-irradiate a body part can be utilized so long as the characteristics of the energy are altered by the relevant blood constituents and so long as these changes can be measured and correlated with changes in blood volume.
Furthermore, it is not critical that the energy be externally supplied. By measuring energetic and/or magnetic properties emitted from the tissue itself, it is possible to practice the invention. For example, by analyzing the magnetic properties attributable to the iron associated with hemoglobin and correlating these properties with changes in the blood volume, the relevant blood constituents can theoretically be quantified. Example 5
It is possible to measure volume changes directly using volume or pressure transduction. For example, a noninvasive blood pressure (NIBP) monitor generates an arterial pressure wave form using an air filled bladder around the finger. This commercially available device rapidly pressurizes and depressurizes the bladder to maintain the finger surrounded by the bladder at nearly constant volume during the pulse. The pressure changes in the bladder can be correlated to volume changes in the finger utilizing standard gas law calculations. These calculations take into account original bladder volume, gas temperature, change in bladder volume and compliance of the bladder.
Example 6
A second approach for determining volume changes is to measure changes in the length of the light path between the light source and photodetector. Then the volume is approximated by modelling the hght path. For example, this model can be a cylinder between emitter and detector with a cross-sectional area equal to the receptive field of the photodetector. When the length of this cylinder changes, such as occurs during pulsatile blood flow, the new volume and, hence, the volume change, are easily determined.
A variety of devices exist that transduce length with high precision. Sonomicrometers, strain gauges, Hall-effect transducers, optical interferometry, and electromagnetic field changes can all be utilized to measure small changes in length. Light intensity itself and light phase changes can also be used to measure distance changes.
Example 7
Measurements or changes in volume can be made passively or actively. Passive measurement would involve, for example, measuring the actual finger expansion and contraction with each pulse. We have been able to show that finger volume does change with each pulse. The finger was placed into a closed rigid chamber (syringe plunger port) filled with an incompressible fluid (water). A pressure transducer (Datascope P3 Module interfaced with a Datascope 870 Monitor, Datascope Corp., Paramus, NJ) was primed with water and connected to the syringe tip. A pulsatile pressure wave form was obtained and reproduced. This provides evidence that the finger does indeed experience volume changes with blood pulsation.
This experiment also demonstrates the feasibility of one method of volume change determinatioa If the pulse amplitude, original finger volume, original chamber size, and compliance of the rigid vessel are known, the volume change in the finger can be determined. This change can be used to calculate the volume change between the LED and photodetector. Example 8
Measurement of actively produced volume changes can also be utilized. Active measurement results from compression and release of tissue at the measurement site by a known distance. If the hght source and the photodetector are brought closer together by an external force, e.g., a motor, which produces a volume change in the receptive field, the same data can be obtained.
This method requires some amount of Hb02 to be displaced from the receptive field.
This procedure can result in the measurement of larger changes in volume compared to passive measurements of volume change during a pulse. Measuring larger volume changes can advantageously reduce experimental error during measurement.
Example 9
The device and method of the subject invention can be utilized in conjunction with life support systems and other medical instrumentations. For example, the subject invention can be used as a sensor for a continuous automatic feedback loop that is designed to maintain Ca02 and/or THb or Hct. An infusion pump, ventilator, and or anesthesia machine can be controlled by the sensor.
The sensor would enable the system to maintain levels of CaO, and/or THb/Hct at levels which are predetermined by the operator of the system.
Example 10 The wavelength and source of Hght employed in the design of the invention can be optimized by those skilled in the art, depending on the particular application. Thus, if direct mHb02 determination is desired, an approximately 660 nm light source can be utilized. If, however, direct mTHb determination is desired, a wavelength near the isobestic point of 805 nm (e.g., 810 nm) can be employed. If direct determination of RHb is sought, a light wavelength near 940 nm can be used. With any of these wavelengths, the remaining unknown parameters (THb and/or Hct and/or RHb and or Ca02) can be determined indirectly with the addition of an accurate Sp02 value using the various formulae discussed above.
Furthermore, the light can be from an LED and/or laser source, such as a laser diode. The laser offers advantages over an LED because its emission spectra is much narrower, its power attenuation with increasing distance is small in comparison, its output is more directional and it is a more ideal beam Thus, reproducibihty and confidence are improved. These advantages allow for easier modeling and subsequent implementation of applications where the distance between hght source and receiver changes. If a laser or other hght emitting source is utilized, the use of fiber-optic technology may also be employed. Fiber-optic cables allow the somewhat motion-, temperature-, and current-sensitive laser or other hght emitting source and detector elements to remain protected and remote from the patient, and also provide an extremely high degree of electrical isolation between the patient and the device.
Example 11
Noise consists of the background hght that enters the photovoltaic cell (PVC) and alters the signal output. Polarizing films can be employed to reduce the effects of background scattered hght. This is achieved by placing a polarizing film in a known orientation between the emitter and tissue and another film in an identical orientation between the tissue and receiver. This configuration prevents randomly polarized hght from entering the PVC. As a consequence, scattered hght from the emitter, as well as ambient light that is rotated with respect to the orientation of the polarizing film, is filtered from the PVC input. All photoplethysmographic devices, including pulse oximeters, would benefit from this application.
The use of polarizing films in this fashion has the added advantage of essentially defining a volume of tissues of similar cross-sectional area to the PVC. The volume's length is the linear distance between emitter and detector. Hence, volume determination is simplified.
Example 12
"Active" volume determination requires a physical displacement of the emitter relative to the PVC. This displacement can be mechanically limited to a known distance. It can also be limited by the tissue pressure upon one of the device elements (i.e., the PVC or light source), or by a combination of pressure and displacement.
Example 13
Light near the isobestic point of Hb02 and RHb (e.g., 810 nm) is absorbed essentially equally well by both species. Therefore, an AC signal representative of pulsatile arterial blood and a DC signal representative of both arterial and venous blood can be obtained. Since arterial and venous THb are the same, either the AC or DC signal can be utihzed to determine THb. Input of Sp02 (which reflects arterial oxygen saturation) then allows arterial oxygen content (Ca02) to be calculated. If a DC signal is also obtained at 660 nm, a total (i.e., combined) arterial and venous oxygen content (CavO^ can be determined. Venous 02 content (C O2) can then be calculated by subtracting Ca02 from Cav02. If one integrates over time (CaOjr-CvO^, one can determine local O2 consumption.
Example 14
The method of actively varying volume can be applied equally well to the new pulse oximeter technologies that employ reflectance or backscatter of hght for their signals. If one varied the slab length, width, or depth from which they receive their signals, essentially a volume change would have been made and similar algorithms to those described above would apply. Therefore, SpOj, THb, HbO,, RHb, Ca02 and local oxygen consumption could each be determined using these new technologies.
Example 15
The claimed device can also be used to determine interstitial fluid content, or state of hydration. Currently, there is no device which can quantitatively measure a patient's hydration status. Such a device would be beneficial in the clinical assessment of delirium, hypotension, tachycardia, and other medical conditions. Thus, it could be used in critical care settings (e.g., emergency rooms) and in chronic care settings (e.g., nursing homes).
The noλ'el device of the subject invention operates by measuring changes in signal strength that occur after a rapid compression (or decompression) of a tissue. The tissue can be thought of as a two compartment system: the intravascular compartment that contains blood and the interstitial compartment that contains body water. By externally deforming the tissue, a hydrostatic pressure change is applied. Since the fluid cannot shift instantaneously between compartments, it shifts first within the compartment with the least resistance to flow. The interstitial fluid is impeded from making rapid shifts because it is trapped in tissue planes and held within the interstitial compartment by hydrophihc molecules. The blood within the intravascular compartment, however, is capable of making rapid shifts. Thus, upon rapid compression, blood would leave the compressed site almost immediately, and only subsequently does the interstitial water begin to leave the compressed region. Likewise, if the tissue was rapidly decompressed, blood would almost immediately refill the vasculature. Following this, the water would refill the interstitial compartment. The rate at which these shifts occur can be used as an indication of hydration status for any given blood pressure.
The measured signal varies with the mass of absorber (i.e., mass of Hb02, RHb, or THb, depending on the wavelength used) in the light path. As reasoned above, after rapid (de)compression, the signal can be expected to vary in a fashion that is related to hydration status. Example 16
It is possible to combine any of the various applications into a new application. For example, a backscatter oximeter may be used to determine mixed venous O2 content in the superficial jugular vein while Ca02 is determined at a peripheral site. Such a combination may provide a good solution to the Fick equation for cardiac output. Another example of a new application is to combine the algorithms that directly determine mTHb and mHbO2 by the new method and design an entirely new pulse oximeter based on measuring vascular volume changes.
Example 17 Living tissue is not the ideal medium for application of the Beer-Lambert law (it is not uniform and scatters hght as well as absorbs it). Ultimately, whether the tissue compression method works in practice must be determined empirically. To verify the method, both animal and human studies were performed, a. Dog Study In this study, we used a weU collimated laser diode (LT010MF, Sharp Corp., Osaka, Japan) with a wavelength of 810 nm As shown in Figure 5, we mounted the laser diode behind a glass slide on one arm of a pair of calipers. On the other arm we mounted a photodiode behind another glass slide. The laser diode module included a control chip (IR3C01 Sharp Corp., Osaka, Japan) to maintain stable power output. The photodiode signal was transmitted by shielded cable to a signal conditioning unit for current to voltage conversion, amplification and filtering. The signal amplitude was then read off from a digital volt meter.
A mongrel dog was anesthetized with a barbiturate infusion. Data were collected by placing the dog's tongue between the glass slides of the caliper assembly and observing voltage readings with the tissue both uncompressed and compressed A block of material was mounted on the caliper slide to determine caliper excursions during compression. THb values were incrementally lowered by intravenous administration of a 0.9% saline solution. After each adπnnistration of saline, blood was drawn and THb determined by CO-Oximeter (model IL-282, Instrument Laboratory, Lexington, MA). Photodiode signal measurements were taken with the tongue in uncompressed and compressed states. Typically, two to five uncompressed and compressed readings were taken for each THb measurement from the drawn blood. Figure 6 shows CO-Oximeter THb versus ]n(l1/l2)/ΔL_, which is the right hand side of (17) except for not including the constant K^n,. A good linear relation was observed (R=0.95) for a wide range of THb values (5.6 to 12.2 g/dL). Some of the variance in the data may be explained by the dog's vigorous diuresis that tended to increase THb with time, thus affecting later measurements taken after blood was drawn. b. Human Volunteers Study
For the human study, we used the device shown in Figure 7. It was constructed from a motorized infusion pump. Again, the laser diode and the photodiode were mounted on opposing arms of the device, behind glass slides. The new device was used to compress finger tip tissue side- to-side and measure photodiode output. Data from five Caucasian and two African American volunteers were taken with tissue compression distances of 2.0 and 2.5 mm. THb values were determined from drawn blood samples by the CO-Oximeter as in the dog study.
These data were plotted after calculating ln(I,/I2)/ΔLB, show a strong linear trend that is consistent across all the volunteers (R=0.85) (Figure 8). There is a certain amount of variance that would be expected in preliminary data.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in hght thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims

Claims
A device for noninvasively determining total hemoglobin, arterial oxygen content, and/or hematocrit in an animal or human, said device comprising a means for photometrically measuring changes in the mass of oxyhemoglobin, total hemoglobin, or reduced hemoglobin, wherein said changes in desired hemoglobin species correspond to measured or known changes in volume.
2. The device, according to claim 1 wherein said measurement of the changes in mass of the hemoglobin species is accomplished by a method comprising one of the following: 1) subjecting a portion of the body to an appropriate energy form and measurement of the attenuation of the energy resulting from the absoφtion of said energy by said body portion; and, 2) measurement of emitted energy from a body part.
3. The device, according to claim 2 wherein a body part is subjected to energy of a form selected from the group consisting of electromagnetic radiation and sound waves.
4. The device, according to claim 3 wherein said energy form is electromagnetic radiation.
5. The device, according to claim 4, wherein said electromagnetic radiation is produced by a laser.
6. The device, according to claim 4, wherein polarizing film is used to reduce background noise and scattered hght.
7. The device, according to claim 6, wherein a first polarizing film is placed between an electromagnetic radiation source and the body portion to be subjected to said radiation, and a second polarizing film is placed between the body portion subjected to said radiation and a device for measurement of the attenuation of said radiation, said polarizing films being aligned such that radiation emitted by the source and passing directly through said body portion will reach said measuring device.
8. The device, according to claim 7, wherein said electromagnetic radiation is produced by a laser.
9. The device, according to claim 4, wherein said appropriate energy form is light having a wavelength in the range from about 400 nm to about 1100 nm.
10. The device, according to claim 9, wherein said wavelength is selected from the group consisting of approximately 660 nm, approximately 810 nm, and approximately 940 nm.
11. The device, according to claim 7, wherein magnetic properties emitted by the body are measured.
12. The device, according to claim 1, wherein said volume change is actively induced by external means.
13. The device, according to claim 12, wherein said volume change is achieved by a mechanically limited and known change in length of a volume of known cross-sectional area.
14. The device, according to claim 1 , wherein said volume change is measured by pressure transduction.
15. The device, according to claim 1, wherein said volume change is approximated by measuring changes in the length of a volume of known cross-sectional area.
16. The device, according to claim 15, wherein said length is measured by means selected from the group consisting of sonomicrometers, strain gauges, Hall-effect transducers, optical interferometry, and electromagnetic field changes.
17. The device, according to claim 1, wherein said volume change is determined by measuring the pulsatile pressure wave form obtained when a body part is immersed in an incompressible fluid.
18. The device, according to claim 17, wherein said incompressible fluid is water.
19. The device, according to claim 1, wherein said body part is selected from the group consisting of hands, fingers, feet, toes, ears, earlobes, nares, lips, and tongue, or any other body part that can be effectively trans-illuminated.
20. The device, according to claim 1, wherein a desired AC or DC signal is input from an oximeter.
21. The device, according to claim 1, further comprising means for photometrically quantifying additional light-absorbing blood components.
22. The device, according to claim 21, wherein said additional hght-absorbing blood components are selected from the group consisting of MetHb and COHb.
23. A device for measuring a blood constituent which comprises: a) a photometric unit comprising a source of radiant energy of known wavelength, between about 400 nm and 11 ,000 nm, and a detector capable of measuring radiant energy between about 400 nm and 11,000 nm, said source and said detector being adapted so as to permit the inteφosition of an animal or human body part therebetween such that said radiant energy emitted from said source must pass through said body part before impinging on said detector; b) a tissue compression unit comprising a mechanical linkage for effecting a controlled amount of tissue compression, said tissue compression unit acting as a housing for said radiant energy source and said detector of (a), such that upon inteφosition of said body part, said tissue compression unit compresses said body part altering by a controllable amount the distance between said radiant energy source and said detector; c) a precision distance measuring unit mounted on said tissue compression unit such that precise measurement of the amount of tissue compression is obtained upon actuation of said tissue compression unit; d) a data collection and conditioning unit for collecting and processing data on the amount of distance varied by said tissue compression unit and the amount of radiant energy received by said detector of said photometric unit; and e) a power supply to provide electrical power for driving the electrical circuits of the foregoing elements a-d.
24. The device of claim 23 wherein said tissue compression unit additionally comprises a force measurement subunit to measure compression forces and to allow monitoring of mechanical arm deformations upon actuation of said tissue compression unit, said force measurement subunit acting as a safety interlock such that upon exceeding a pre-set limit, the force measurement subunit interrupts power to the tissue compression unit, said force measurement subunit also providing the device operator with the option of entering cahbration corrections for known individual characteristics such as elevated blood pressure, which may otherwise provide an undesirable bias to the collected data.
25. The device of claim 23 wherein, in addition to said data collection and conditioning unit, collecting and processing said data on the amount of distance varied by said tissue compression unit and the data from said photometric unit, said unit further performs the necessary calculations to provide a continuous readout for the given blood component being measured.
26. A non-invasive method for measuring blood hemoglobin, hematocrit, oxygen content, glucose, bilirubin, cholesterol or other blood components which comprises using the device of claim 25.
27. The method of claim 26 wherein a wavelength of 810 nm is used for measuring hemoglobin and a wavelength of 9700 nm is used for measuring blood glucose.
PCT/US1996/009148 1995-06-07 1996-06-06 Method for noninvasive intermittent and/or continuous hemoglobin, arterial oxygen content, and hematocrit determination WO1996039927A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62561/96A AU6256196A (en) 1995-06-07 1996-06-06 Method for noninvasive intermittent and/or continuous hemogl obin, arterial oxygen content, and hematocrit determination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47385595A 1995-06-07 1995-06-07
US08/473,855 1995-06-07

Publications (1)

Publication Number Publication Date
WO1996039927A1 true WO1996039927A1 (en) 1996-12-19

Family

ID=23881299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009148 WO1996039927A1 (en) 1995-06-07 1996-06-06 Method for noninvasive intermittent and/or continuous hemoglobin, arterial oxygen content, and hematocrit determination

Country Status (2)

Country Link
AU (1) AU6256196A (en)
WO (1) WO1996039927A1 (en)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025514A1 (en) * 1996-12-11 1998-06-18 Alliance Pharmaceutical Corp. System and methods for measuring oxygenation parameters
WO2000028887A1 (en) * 1998-11-18 2000-05-25 Alfons Krug Device for non-invasively detecting the oxygen metabolism in tissues
WO2009040740A1 (en) * 2007-09-27 2009-04-02 Koninklijke Philips Electronics N.V. Blood oximeter
US7684842B2 (en) 2006-09-29 2010-03-23 Nellcor Puritan Bennett Llc System and method for preventing sensor misuse
US7809418B2 (en) 2007-10-04 2010-10-05 The Curators Of The University Of Missouri Optical device components
US7961304B2 (en) 2007-09-13 2011-06-14 The Curators Of The University Of Missouri Optical device components
US7961305B2 (en) 2007-10-23 2011-06-14 The Curators Of The University Of Missouri Optical device components
US8064976B2 (en) 2003-10-03 2011-11-22 Can Ince Systems and methods for sidesstream dark field imaging
US8219170B2 (en) 2006-09-20 2012-07-10 Nellcor Puritan Bennett Llc System and method for practicing spectrophotometry using light emitting nanostructure devices
US8265724B2 (en) 2007-03-09 2012-09-11 Nellcor Puritan Bennett Llc Cancellation of light shunting
US8280469B2 (en) 2007-03-09 2012-10-02 Nellcor Puritan Bennett Llc Method for detection of aberrant tissue spectra
US8315685B2 (en) 2006-09-27 2012-11-20 Nellcor Puritan Bennett Llc Flexible medical sensor enclosure
US8340738B2 (en) 2008-05-22 2012-12-25 The Curators Of The University Of Missouri Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
WO2013011476A3 (en) * 2011-07-20 2013-03-14 Ben Gurion University Of The Negev, Research And Development Authority A non-invasive device and method for measuring bilirubin levels
US8552359B2 (en) 2009-04-01 2013-10-08 The Curators of the Univesity of Missouri Optical spectroscopy device for non-invasive blood glucose detection and associated method of use
US8600469B2 (en) 2005-09-29 2013-12-03 Covidien Lp Medical sensor and technique for using the same
US8610769B2 (en) 2011-02-28 2013-12-17 Covidien Lp Medical monitor data collection system and method
US8622916B2 (en) 2008-10-31 2014-01-07 Covidien Lp System and method for facilitating observation of monitored physiologic data
US8862196B2 (en) 2001-05-17 2014-10-14 Lawrence A. Lynn System and method for automatic detection of a plurality of SP02 time series pattern types
US8965473B2 (en) 2005-09-29 2015-02-24 Covidien Lp Medical sensor for reducing motion artifacts and technique for using the same
US8968193B2 (en) 2008-09-30 2015-03-03 Covidien Lp System and method for enabling a research mode on physiological monitors
US9031793B2 (en) 2001-05-17 2015-05-12 Lawrence A. Lynn Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions
US9042952B2 (en) 1997-01-27 2015-05-26 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US9131861B2 (en) 2004-11-30 2015-09-15 Academisch Medisch Centrum Pulsed lighting imaging systems and methods
WO2015161002A1 (en) * 2014-04-15 2015-10-22 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid receiver and corresponding error
US9468378B2 (en) 1997-01-27 2016-10-18 Lawrence A. Lynn Airway instability detection system and method
US9521971B2 (en) 1997-07-14 2016-12-20 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US9595104B2 (en) 2012-05-14 2017-03-14 Gauss Surgical, Inc. System and method for estimating a quantity of a blood component in a fluid canister
US9646375B2 (en) 2011-07-09 2017-05-09 Gauss Surgical, Inc. Method for setting a blood transfusion parameter
US9652655B2 (en) 2011-07-09 2017-05-16 Gauss Surgical, Inc. System and method for estimating extracorporeal blood volume in a physical sample
US9773320B2 (en) 2014-04-15 2017-09-26 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid canister
US9824441B2 (en) 2014-04-15 2017-11-21 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid canister
US9870625B2 (en) 2011-07-09 2018-01-16 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid receiver and corresponding error
US9895068B2 (en) 2008-06-30 2018-02-20 Covidien Lp Pulse oximeter with wait-time indication
US9936906B2 (en) 2012-05-14 2018-04-10 Gauss Surgical, Inc. System and methods for managing blood loss of a patient
US10076276B2 (en) 2008-02-19 2018-09-18 Covidien Lp Methods and systems for alerting practitioners to physiological conditions
US10354753B2 (en) 2001-05-17 2019-07-16 Lawrence A. Lynn Medical failure pattern search engine
US10424060B2 (en) 2012-07-09 2019-09-24 Gauss Surgical, Inc. Method for estimating blood component quantities in surgical textiles
US10426356B2 (en) 2011-07-09 2019-10-01 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid receiver and corresponding error
US10542919B2 (en) 2008-03-25 2020-01-28 St. Louis Medical Devices, Inc. Method and system for non-invasive blood glucose detection utilizing spectral data of one or more components other than glucose
US10555675B2 (en) 2015-05-15 2020-02-11 Gauss Surgical, Inc. Method for projecting blood loss of a patient during a surgery
US10641644B2 (en) 2012-07-09 2020-05-05 Gauss Surgical, Inc. System and method for estimating an amount of a blood component in a volume of fluid
US10789710B2 (en) 2015-05-15 2020-09-29 Gauss Surgical, Inc. Methods and systems for characterizing fluids from a patient
US11109941B2 (en) 2017-01-02 2021-09-07 Gauss Surgical, Inc. Tracking surgical items with prediction of duplicate imaging of items
US11229368B2 (en) 2017-01-13 2022-01-25 Gauss Surgical, Inc. Fluid loss estimation based on weight of medical items
US11357412B2 (en) 2018-11-20 2022-06-14 42 Health Sensor Holdings Ltd. Wearable cardiovascular monitoring device
US11504037B2 (en) 2015-05-15 2022-11-22 Gauss Surgical, Inc. Systems and methods for assessing fluids from a patient

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004353A2 (en) * 1988-10-28 1990-05-03 Dietrich Gravenstein Method for noninvasive intermittent and/or continuous hemoglobin, arterial oxygen content, and hematocrit determination
US4927264A (en) * 1987-12-02 1990-05-22 Omron Tateisi Electronics Co. Non-invasive measuring method and apparatus of blood constituents
WO1990007905A1 (en) * 1989-01-19 1990-07-26 Futrex, Inc. Non-invasive measurement of blood glucose
EP0619981A1 (en) * 1993-04-12 1994-10-19 Ohmeda Inc. Arterial blood monitoring probe
US5361758A (en) * 1988-06-09 1994-11-08 Cme Telemetrix Inc. Method and device for measuring concentration levels of blood constituents non-invasively

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927264A (en) * 1987-12-02 1990-05-22 Omron Tateisi Electronics Co. Non-invasive measuring method and apparatus of blood constituents
US5361758A (en) * 1988-06-09 1994-11-08 Cme Telemetrix Inc. Method and device for measuring concentration levels of blood constituents non-invasively
WO1990004353A2 (en) * 1988-10-28 1990-05-03 Dietrich Gravenstein Method for noninvasive intermittent and/or continuous hemoglobin, arterial oxygen content, and hematocrit determination
WO1990007905A1 (en) * 1989-01-19 1990-07-26 Futrex, Inc. Non-invasive measurement of blood glucose
EP0619981A1 (en) * 1993-04-12 1994-10-19 Ohmeda Inc. Arterial blood monitoring probe

Cited By (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6390977B1 (en) 1995-06-07 2002-05-21 Alliance Pharmaceutical Corp. System and methods for measuring oxygenation parameters
WO1998025514A1 (en) * 1996-12-11 1998-06-18 Alliance Pharmaceutical Corp. System and methods for measuring oxygenation parameters
US9042952B2 (en) 1997-01-27 2015-05-26 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US9468378B2 (en) 1997-01-27 2016-10-18 Lawrence A. Lynn Airway instability detection system and method
US9521971B2 (en) 1997-07-14 2016-12-20 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
WO2000028887A1 (en) * 1998-11-18 2000-05-25 Alfons Krug Device for non-invasively detecting the oxygen metabolism in tissues
US6859658B1 (en) 1998-11-18 2005-02-22 Lea Medizintechnik Gmbh Device for non-invasively detecting the oxygen metabolism in tissues
CN100381095C (en) * 1998-11-18 2008-04-16 Lea医药技术有限公司 Device for non-invasively detecting the oxygen metabolism in tissues
US10058269B2 (en) 2000-07-28 2018-08-28 Lawrence A. Lynn Monitoring system for identifying an end-exhalation carbon dioxide value of enhanced clinical utility
US8932227B2 (en) 2000-07-28 2015-01-13 Lawrence A. Lynn System and method for CO2 and oximetry integration
US8862196B2 (en) 2001-05-17 2014-10-14 Lawrence A. Lynn System and method for automatic detection of a plurality of SP02 time series pattern types
US10354753B2 (en) 2001-05-17 2019-07-16 Lawrence A. Lynn Medical failure pattern search engine
US9031793B2 (en) 2001-05-17 2015-05-12 Lawrence A. Lynn Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions
US10032526B2 (en) 2001-05-17 2018-07-24 Lawrence A. Lynn Patient safety processor
US10366790B2 (en) 2001-05-17 2019-07-30 Lawrence A. Lynn Patient safety processor
US10297348B2 (en) 2001-05-17 2019-05-21 Lawrence A. Lynn Patient safety processor
US11439321B2 (en) 2001-05-17 2022-09-13 Lawrence A. Lynn Monitoring system for identifying an end-exhalation carbon dioxide value of enhanced clinical utility
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US8064976B2 (en) 2003-10-03 2011-11-22 Can Ince Systems and methods for sidesstream dark field imaging
US8452384B2 (en) 2003-10-03 2013-05-28 MicroVision Medical Holdings B.V. Systems and methods for sidesstream dark field imaging
US9131861B2 (en) 2004-11-30 2015-09-15 Academisch Medisch Centrum Pulsed lighting imaging systems and methods
US8965473B2 (en) 2005-09-29 2015-02-24 Covidien Lp Medical sensor for reducing motion artifacts and technique for using the same
US8600469B2 (en) 2005-09-29 2013-12-03 Covidien Lp Medical sensor and technique for using the same
US8219170B2 (en) 2006-09-20 2012-07-10 Nellcor Puritan Bennett Llc System and method for practicing spectrophotometry using light emitting nanostructure devices
US8315685B2 (en) 2006-09-27 2012-11-20 Nellcor Puritan Bennett Llc Flexible medical sensor enclosure
US7684842B2 (en) 2006-09-29 2010-03-23 Nellcor Puritan Bennett Llc System and method for preventing sensor misuse
US8280469B2 (en) 2007-03-09 2012-10-02 Nellcor Puritan Bennett Llc Method for detection of aberrant tissue spectra
US8265724B2 (en) 2007-03-09 2012-09-11 Nellcor Puritan Bennett Llc Cancellation of light shunting
US7961304B2 (en) 2007-09-13 2011-06-14 The Curators Of The University Of Missouri Optical device components
US8417307B2 (en) 2007-09-27 2013-04-09 Koninklijke Philips Electronics N.V. Blood oximeter
WO2009040740A1 (en) * 2007-09-27 2009-04-02 Koninklijke Philips Electronics N.V. Blood oximeter
US7809418B2 (en) 2007-10-04 2010-10-05 The Curators Of The University Of Missouri Optical device components
US7961305B2 (en) 2007-10-23 2011-06-14 The Curators Of The University Of Missouri Optical device components
US11298076B2 (en) 2008-02-19 2022-04-12 Covidien Lp Methods and systems for alerting practitioners to physiological conditions
US10076276B2 (en) 2008-02-19 2018-09-18 Covidien Lp Methods and systems for alerting practitioners to physiological conditions
US10542919B2 (en) 2008-03-25 2020-01-28 St. Louis Medical Devices, Inc. Method and system for non-invasive blood glucose detection utilizing spectral data of one or more components other than glucose
US11147482B2 (en) 2008-03-25 2021-10-19 St. Louis Medical Devices, Inc. Method and system for non-invasive blood glucose measurement using signal change of the non-glucose components induced by the presence of glucose
US9788764B2 (en) 2008-05-22 2017-10-17 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US11076781B2 (en) 2008-05-22 2021-08-03 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US10973442B2 (en) 2008-05-22 2021-04-13 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US9629576B2 (en) 2008-05-22 2017-04-25 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US10959650B2 (en) 2008-05-22 2021-03-30 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US9566024B2 (en) 2008-05-22 2017-02-14 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US8340738B2 (en) 2008-05-22 2012-12-25 The Curators Of The University Of Missouri Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US11553859B2 (en) 2008-05-22 2023-01-17 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US9814415B2 (en) 2008-05-22 2017-11-14 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US9579049B2 (en) 2008-05-22 2017-02-28 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US10080515B2 (en) 2008-05-22 2018-09-25 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US9877670B2 (en) 2008-05-22 2018-01-30 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US10070809B2 (en) 2008-05-22 2018-09-11 St. Louis Medical Devices, Inc. Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis
US9895068B2 (en) 2008-06-30 2018-02-20 Covidien Lp Pulse oximeter with wait-time indication
US8968193B2 (en) 2008-09-30 2015-03-03 Covidien Lp System and method for enabling a research mode on physiological monitors
US8622916B2 (en) 2008-10-31 2014-01-07 Covidien Lp System and method for facilitating observation of monitored physiologic data
US9993208B2 (en) 2008-10-31 2018-06-12 Covidien Lp System and method for facilitating observation of monitored physiologic data
US8552359B2 (en) 2009-04-01 2013-10-08 The Curators of the Univesity of Missouri Optical spectroscopy device for non-invasive blood glucose detection and associated method of use
US8610769B2 (en) 2011-02-28 2013-12-17 Covidien Lp Medical monitor data collection system and method
US9870625B2 (en) 2011-07-09 2018-01-16 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid receiver and corresponding error
US10957179B2 (en) 2011-07-09 2021-03-23 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid receiver and corresponding error
US11783503B2 (en) 2011-07-09 2023-10-10 Gauss Surgical Inc. Systems and method for estimating extracorporeal blood volume in a physical sample
US11222189B2 (en) 2011-07-09 2022-01-11 Gauss Surgical, Inc. System and method for estimating extracorporeal blood volume in a physical sample
US10426356B2 (en) 2011-07-09 2019-10-01 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid receiver and corresponding error
US10528782B2 (en) 2011-07-09 2020-01-07 Gauss Surgical, Inc. System and method for estimating extracorporeal blood volume in a physical sample
US9652655B2 (en) 2011-07-09 2017-05-16 Gauss Surgical, Inc. System and method for estimating extracorporeal blood volume in a physical sample
US11670143B2 (en) 2011-07-09 2023-06-06 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid receiver and corresponding error
US9646375B2 (en) 2011-07-09 2017-05-09 Gauss Surgical, Inc. Method for setting a blood transfusion parameter
EP2734113A4 (en) * 2011-07-20 2015-03-18 Univ Ben Gurion A non-invasive device and method for measuring bilirubin levels
CN103747732A (en) * 2011-07-20 2014-04-23 内盖夫本·古里安大学研究与发展机构 A non-invasive device and method for measuring bilirubin levels
US9173603B2 (en) 2011-07-20 2015-11-03 Jonathan Molcho Non-invasive device and method for measuring bilirubin levels
WO2013011476A3 (en) * 2011-07-20 2013-03-14 Ben Gurion University Of The Negev, Research And Development Authority A non-invasive device and method for measuring bilirubin levels
US11712183B2 (en) 2012-05-14 2023-08-01 Gauss Surgical Inc. System and methods for managing blood loss of a patient
US10863933B2 (en) 2012-05-14 2020-12-15 Gauss Surgical, Inc. System and methods for managing blood loss of a patient
US10706541B2 (en) 2012-05-14 2020-07-07 Gauss Surgical, Inc. System and method for estimating a quantity of a blood component in a fluid canister
US9595104B2 (en) 2012-05-14 2017-03-14 Gauss Surgical, Inc. System and method for estimating a quantity of a blood component in a fluid canister
US10282839B2 (en) 2012-05-14 2019-05-07 Gauss Surgical, Inc. System and method for estimating a quantity of a blood component in a fluid canister
US11836915B2 (en) 2012-05-14 2023-12-05 Gauss Surgical Inc. System and method for estimating a quantity of a blood component in a fluid canister
US9936906B2 (en) 2012-05-14 2018-04-10 Gauss Surgical, Inc. System and methods for managing blood loss of a patient
US10641644B2 (en) 2012-07-09 2020-05-05 Gauss Surgical, Inc. System and method for estimating an amount of a blood component in a volume of fluid
US10424060B2 (en) 2012-07-09 2019-09-24 Gauss Surgical, Inc. Method for estimating blood component quantities in surgical textiles
US9824441B2 (en) 2014-04-15 2017-11-21 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid canister
US9773320B2 (en) 2014-04-15 2017-09-26 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid canister
WO2015161002A1 (en) * 2014-04-15 2015-10-22 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid receiver and corresponding error
US11504037B2 (en) 2015-05-15 2022-11-22 Gauss Surgical, Inc. Systems and methods for assessing fluids from a patient
US11666226B2 (en) 2015-05-15 2023-06-06 Gauss Surgical, Inc. Method for projecting blood loss of a patient during a surgery
US11410311B2 (en) 2015-05-15 2022-08-09 Gauss Surgical, Inc. Methods and systems for characterizing fluids from a patient
US11727572B2 (en) 2015-05-15 2023-08-15 Gauss Surgical Inc. Methods and systems for characterizing fluids from a patient
US10555675B2 (en) 2015-05-15 2020-02-11 Gauss Surgical, Inc. Method for projecting blood loss of a patient during a surgery
US10789710B2 (en) 2015-05-15 2020-09-29 Gauss Surgical, Inc. Methods and systems for characterizing fluids from a patient
US11176663B2 (en) 2015-12-23 2021-11-16 Gauss Surgical, Inc. Method for estimating blood component quantities in surgical textiles
US11333545B2 (en) 2015-12-23 2022-05-17 Gauss Surgical, Inc. System and method for estimating an amount of a blood component in a volume of fluid
US11282194B2 (en) 2015-12-23 2022-03-22 Gauss Surgical, Inc. Method for estimating blood component quantities in surgical textiles
US11790637B2 (en) 2015-12-23 2023-10-17 Gauss Surgical Inc. Method for estimating blood component quantities in surgical textiles
US11109941B2 (en) 2017-01-02 2021-09-07 Gauss Surgical, Inc. Tracking surgical items with prediction of duplicate imaging of items
US11922646B2 (en) 2017-01-02 2024-03-05 Gauss Surgical Inc. Tracking surgical items with prediction of duplicate imaging of items
US11229368B2 (en) 2017-01-13 2022-01-25 Gauss Surgical, Inc. Fluid loss estimation based on weight of medical items
US11357412B2 (en) 2018-11-20 2022-06-14 42 Health Sensor Holdings Ltd. Wearable cardiovascular monitoring device

Also Published As

Publication number Publication date
AU6256196A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
WO1996039927A1 (en) Method for noninvasive intermittent and/or continuous hemoglobin, arterial oxygen content, and hematocrit determination
US5101825A (en) Method for noninvasive intermittent and/or continuous hemoglobin, arterial oxygen content, and hematocrit determination
US8078250B2 (en) Method for spectrophotometric blood oxygenation monitoring
US6064898A (en) Non-invasive blood component analyzer
US6456862B2 (en) Method for non-invasive spectrophotometric blood oxygenation monitoring
US6151516A (en) Active pulse blood constituent monitoring
US7254432B2 (en) Method and device for non-invasive measurements of blood parameters
US20030212316A1 (en) Method and apparatus for determining blood parameters and vital signs of a patient
US8818472B2 (en) Methods and devices for noninvasive measurement of energy absorbers in blood
JP2004523320A (en) Method and apparatus for improving the accuracy of non-invasive hematocrit measurements
WO1999065384A1 (en) Non-invasive optical measurement of a blood constituent
Kraitl et al. Non-invasive measurement of blood components
Kraitl et al. Non-invasive measurement of blood and tissue parameters based on VIS-NIR spectroscopy
Damianou The wavelength dependence of the photoplethysmogram and its implication to pulse oximetry
Yoon et al. Robust design of finger probe in non-invasive total haemoglobin monitor
Yelderman et al. Real time oximetry
Kumar V et al. Pulse oximetry for the measurement of oxygen saturation in arterial blood
Harrison et al. Optical measurement of tissue oxygen saturation
Abdallah et al. Towards noninvasive monitoring of total hemoglobin concentration and fractional oxygen saturation based on earlobe pulse oximetry
Joglekar et al. A review of blood gas sensors and a proposed portable solution
Komalla Pulse Oximetry: An Introduction
Uglov et al. DEVELOPMENT OF THE REFLECTION-TYPE PULSE OXIMETER
Kemeny et al. Nonpulsatile and noninvasive transmittance and reflectance tissue-bed oximetry
Severinghaus Oximetry I: Nomenclature, History, Accuracy and Uses
Diwate et al. Correlation of Ratio of Ratio of Near Infrared Vs Infrared Photoplethysmograph Spectroscopy for the Non-Invasive Measurement of Haemoglobin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA